What is SilcsBio?
SilcsBio is at the forefront of computer-aided drug design (CADD), leveraging its proprietary software solutions, including SILCS, SILCS-Biologics, and CGenFF, to accelerate drug discovery. The company provides essential consultation and training services, empowering pharmaceutical and biotechnology firms to streamline their development pipelines and reduce associated costs. By generating detailed 3D free energy maps, SilcsBio's technology is instrumental in identifying promising drug targets, thereby optimizing the drug development process for its clients.
How much funding has SilcsBio raised?
SilcsBio has raised a total of $1.3M across 1 funding round:
Other Financing Round
$1.3M
Other Financing Round (2016): $1.3M with participation from National Institute of Health
Key Investors in SilcsBio
National Institute of Health
The National Institute of Health is a prominent governmental research agency that likely supports advancements in biotechnology and pharmaceutical research through its investments.
What's next for SilcsBio?
With the recent major strategic investment, SilcsBio is poised to further enhance its CADD platform and expand its market reach. This capital will likely fuel advancements in its software capabilities, enabling deeper integration into the drug discovery workflows of its partners. The company's focus on accelerating timelines and reducing costs positions it as a key player in the competitive biotech landscape, suggesting future growth and potential for further strategic alliances or funding rounds as it continues to innovate in the pharmaceutical R&D sector.
See full SilcsBio company page
